HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 3,001-3,012 of 4,505
Behavioral study icon
CompletedNCT02896374

Normal and Abnormal ERP During ToM and Emotional Conflicts in Schizophrenia

Official study title

Normal and Abnormal Event Related Potentials During Attribution of Intentions to Others and Resolution of Emotional Conflicts in Schizophrenia

This study has finished and is no longer accepting participants.

In Le Chesnay
SchizophreniaBehavioural studyAges 18–60
Countries
France
Sponsor
Versailles Hospital
Drug study icon
WithdrawnNCT02603458

NRX-1074 in Early Course Schizophrenia

Official study title

A Placebo-controlled Two-dose Trial of NRX-1074 Early in the Course of Schizophrenia

This study was withdrawn before enrollment.

Multiple locations, including Boston
SchizophreniaMedication studyAges 18–50
Countries
United States
Sponsor
NYU Langone Health
Drug study icon
CompletedNCT02704962

Olanzapine vs. Low-dose Olanzapine Plus Trifluoperazine

Official study title

A Randomized, Double-blind, Comparison of the Efficacy and Safety of Olanzapine Versus Low-dose Olanzapine Plus Low-dose Trifluoperazine in the Treatment of Schizophrenia

This study has finished and is no longer accepting participants.

In Kaohsiung City
SchizophreniaMedication studyAges 18–55
Countries
Taiwan
Sponsor
Kaohsiung Kai-Suan Psychiatric Hospital
Drug study icon
WithdrawnNCT00964041

Once Weekly D-cycloserine for Schizophrenia

Official study title

Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia.

This study was withdrawn before enrollment.

In Boston
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
Massachusetts General Hospital (Hospital / academic medical center)
Device study icon
CompletedNCT02219009

Usability of the Medical Information Device #1 System for schizophrenia

Official study title

A Multicenter, 8-week, Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adult Subjects With Schizophrenia Who Are Treated With Oral Aripiprazole

This study has finished and is no longer accepting participants.

Multiple locations, including Cerritos
SchizophreniaDevice studyAges 18–65
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Drug study icon
WithdrawnNCT00425815

Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia

Official study title

A Placebo-Controlled Trial of Org 24448 (Ampakine) Added to Atypical Antipsychotics in Patients With Schizophrenia

This study was withdrawn before enrollment.

Multiple locations, including Los Angeles
SchizophreniaMedication studyAges 18–55
Countries
United States
Sponsor
University of California, Los Angeles
Drug study icon
TerminatedNCT00506909

Oxytocin Add on Study for Stable Schizophrenic Patients

Official study title

Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study of Intranasal Oxytocin Augmentation of Antipsychotic Medication in Schizophrenia Patients

This study ended early.

In San Diego
SchizophreniaMedication studyAges 18+
Countries
United States
Sponsor
David Feifel
Drug study icon
CompletedNCT02568709

Oxytocin MEG Study

Official study title

Effects of Oxytocin on Neural Activation Patterns During Social Cognitive Tasks in Patients With Schizophrenia

This study has finished and is no longer accepting participants.

In San Francisco
SchizophreniaMedication studyAges 18–40
Countries
United States
Sponsor
University of California, San Francisco
Other study type icon
TerminatedNCT01244542

Pain and Schizophrenia

This study ended early.

Multiple locations, including Besançon
SchizophreniaInterventional studyAges 18–55
Countries
France
Sponsor
University Hospital, Strasbourg, France

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.